Hollywood Media Co (NSTM PINK) stock market data APIs
$0.0101
0(0%)
as of March 21, 2025
Hollywood Media Co Financial Data Overview
NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of stem cell-based diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.
Prev. Close
0.0101
Open
0.0101
High
0.0101
Low
0.0101
52 wk Range
0.01-0.07
Market Cap
469 K
Shares Outstanding
46 882 K
Revenue
18 000
EPS
-0.0526
Beta
0.418
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Hollywood Media Co data using free add-ons & libraries
Get Hollywood Media Co Fundamental Data
Hollywood Media Co Fundamental data includes:
- Net Revenue: 18 000
- EBITDA: -4 808 822
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-15
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Hollywood Media Co News
New
NovelStem Increases NewStem Ownership to 33% as NewStem Prepares for First-Half 2021 FDA Filing for Approval of its Stem-Cell Based Anti-Cancer Drug Resistance Diagnostic; NovelStem Initiates Process to Become Publicly-Reporting with S.E.C. and to Up-List its Shares
BOCA RATON, Fla. and JERUSALEM, Dec. 01, 2020 (GLOBE NEWSWIRE) -- NovelStem International Corp.(OTC Pink: NSTM), a biotechnology company focused on its stem cell-based technology platform, developed...
NovelStem Announces New Research Collaborations for Stem-Cell Technology Platform in Cancer Immunotherapy and COVID-19 Resistance; Reports Progress Identifying Genetic Resistance to Additional Anti-Cancer Treatments
Screening of resistance diagnostics completed for twelve standard-of-care cancer treatments representing a significant portion of cancer treatment protocols. COVID-19 research collaboration initiated ...
NovelStem Increases NewStem Ownership to 27.3% Following Achievement of Development Milestones for Stem-Cell-Based Cancer Treatments Resistance Diagnostic
BOCA RATON, Fla. and JERUSALEM, Israel, Dec. 16, 2019 (GLOBE NEWSWIRE) -- NovelStem International Corp. (OTC Pink: NSTM), a biotechnology company focused on stem-cell-based diagnostic technology to ...
NovelStem Provides Shareholder Update
BOCA RATON, Fla., May 08, 2019 (GLOBE NEWSWIRE) -- NovelStem International Corp. (OTC Pink: NSTM) is focused on the substantial commercial potential of stem-cell-based diagnostic technology to aid t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
